Recommendations for managing a suboptimal response to biologics for moderate-to-severe psoriasis: A Belgian perspective

J Dermatolog Treat. 2016;27(2):128-33. doi: 10.3109/09546634.2015.1086476. Epub 2015 Sep 29.

Abstract

Over the past decade, biologics have become the gold standard in the treatment of moderate-to-severe psoriasis for patients who have failed or who have contraindications to traditional systemic treatments. However, although practical recommendations on how to treat a suboptimal response to biologics exist in other chronic inflammatory diseases, they are only just beginning to emerge for psoriasis. This article aims to formulate recommendations in the case of a suboptimal response of psoriasis to biologics in the Belgian setting. A Belgian taskforce of psoriasis experts was convened to review the results of a literature search and formulate recommendations based on the available evidence and provide expert opinion to address gaps in the evidence. The taskforce has proposed a treatment algorithm for patients with a primary non-response or a secondary loss of response to help address an unmet need. Expert recommendations have been developed to address treatment strategies in case of a primary or secondary suboptimal response to biologics in the treatment of moderate-to-severe psoriasis in Belgium.

Keywords: Algorithm; biologics; immunogenicity; psoriasis; secondary failure.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biological Products / adverse effects
  • Biological Products / therapeutic use*
  • Humans
  • Psoriasis / therapy*

Substances

  • Biological Products